Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

BRIEF-Dr.Reddy's Labs' U.S. Unit Announces ANDA Filing For Migraine Candidate [Reuters]

Dr. Reddy's Laboratories Ltd (RDY) 
US:NYSE Investor Relations: drreddys.com/investors
Company Research Source: Reuters
BRIEF-Dr.Reddy's Labs' U.S. Unit Announces ANDA Filing For Migraine Candidate | Reuters Reuters Staff 1 Min Read April 2 (Reuters) - Dr.Reddy’s Laboratories Ltd: * CO, U.S. UNIT PROMIUS PHARMA ANNOUNCE FILING OF AN NDA FOR MIGRAINE CANDIDATE * UPON APPROVAL, PRODUCT WILL BE COMMERCIALISED BY PROMIUS PHARMA Source text: bit.ly/2GOk7ib Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved. Show less Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
RDY alerts

from News Quantified
Opt-in for
RDY alerts

from News Quantified